Literature DB >> 29606028

Renoprotective effect of nifuroxazide in diabetes-induced nephropathy: impact on NFκB, oxidative stress, and apoptosis.

Nehal M Elsherbiny1,2, Sawsan A Zaitone3,4, Hala M F Mohammad5, Mohamed El-Sherbiny6,7.   

Abstract

The prevalence of diabetes mellitus (DM) is drastically increased worldwide. Diabetic nephropathy (DN) is a microvascular complication of DM and a common cause of end stage renal disease (ESRD). DN has been recently reported as the most common cause among ESRD patients. Shortage of a definitive cure for DN and the social and economic burden of this disease provide considerable impetus for development of new therapies. In the present study, we evaluated the effect of nifuroxazide, a potent inhibitor of Janus kinase/signal transducers and activators of transcription (JAK2/STAT3), on nuclear factor kappa B (NFκB), oxidative stress, and apoptosis in diabetic kidney. Following induction of diabetes by single dose of streptozotocin (50 mg/kg), nifuroxazide was administrated to diabetic rats (25 mg/kg/day, orally) for 8 weeks. Our results showed that nifuroxazide treatment, attenuated diabetes-induced damage in renal structure, ameliorated oxidative stress, triggered antioxidant defense, reduced NFκB nuclear translocation and cleaved caspase-3 expression and down regulated the activity of apoptotic enzymes (caspase-3/caspase-8/caspase-9) in diabetic kidney. In conclusion, nifuroxazide exhibited renoprotective effect in diabetic kidney via dampening NFκB activation, oxidative stress, and apoptosis.

Entities:  

Keywords:  Diabetic nephropathy; NFκB; apoptosis; nifuroxazide; oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29606028     DOI: 10.1080/15376516.2018.1459995

Source DB:  PubMed          Journal:  Toxicol Mech Methods        ISSN: 1537-6516            Impact factor:   2.987


  5 in total

1.  Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury-Insight into Oxidative Injury/Inflammation/Apoptosis Modulation.

Authors:  Mohamed El-Sherbiny; Mohamed El-Shafey; Eman Said; Gehan Ahmed Shaker; Mohamed El-Dosoky; Hasnaa Ali Ebrahim; Sally Yussef Abed; Khalid M Ibraheem; Ahmed Mohsen Faheem; Muntazar AlMutawa; Bayader Alatawi; Nehal M Elsherbiny
Journal:  Life (Basel)       Date:  2022-05-21

2.  The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats.

Authors:  Mahrokh Samadi; Shiva Gholizadeh-Ghaleh Aziz; Roya Naderi
Journal:  Cell Stress Chaperones       Date:  2020-10-12       Impact factor: 3.667

3.  Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.

Authors:  Cailing Gan; Qianyu Zhang; Hongyao Liu; Guan Wang; Liqun Wang; Yali Li; Zui Tan; Wenya Yin; Yuqin Yao; Yongmei Xie; Liang Ouyang; Luoting Yu; Tinghong Ye
Journal:  Respir Res       Date:  2022-02-16

4.  Nifuroxazide Mitigates Angiogenesis in Ehlrich's Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling.

Authors:  Mohamed El-Sherbiny; Rehab M El-Sayed; Mohamed A Helal; Afaf T Ibrahiem; Hoda S Elmahdi; Mohamed Ahmed Eladl; Shymaa E Bilay; Asma M Alshahrani; Mona K Tawfik; Ziad E Hamed; Amany O Mohamed; Sawsan A Zaitone
Journal:  Molecules       Date:  2021-11-13       Impact factor: 4.411

5.  Nifuroxazide ameliorates lipid and glucose metabolism in palmitate-induced HepG2 cells.

Authors:  Jing-Yi Liu; Yi-Chen Zhang; Li-Ni Song; Lin Zhang; Fang-Yuan Yang; Xiao-Rong Zhu; Zhi-Qiang Cheng; Xi Cao; Jin-Kui Yang
Journal:  RSC Adv       Date:  2019-11-29       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.